Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as [18F]MK-0947
MK-0947 · 1 trial · 3 indications
Incidence of adverse events (AEs) following administration
Radiation absorbed dose estimates following administration derived from PET imaging and dosimetry calculations.
| Arm | Type | Description |
|---|---|---|
| Part 1 - Brain Imaging | EXPERIMENTAL | Participants receive \[18F\]MK-0947 for PET imaging of the brain. |
| Part 2 - Dosimetry | EXPERIMENTAL | Healthy participants receive \[18F\]MK-0947 for whole-body dosimetry. |
| Name | Type | Description |
|---|---|---|
| [18F]MK-0947 | DRUG | PET radiopharmaceutical selective for α-synuclein, administered IV at doses up to 10 mCi. |
Inclusion Criteria: * Signed informed consent prior to any study procedures * Women of childbearing potential: abstinent or use 2 contraception methods (one barrier) during study and 90 days post last injection * Men: use 2 contraception methods and refrain from sperm donation during study and 90 d...
Top 15 of 23 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | SUPN | 2 | PHASE3 | Onapgo (SPN-830) |
| Prothena Corp. Plc | PRTA | 3 | PHASE3 | Prasinezumab |
| Denali Therapeutics Inc. | DNLI | 1 | PHASE2 | BIIB122 |
| Bayer | BAYRY | 4 | PHASE3 | bemdaneprocel, AB-1005 |
| Biohaven Ltd. | BHVN | 1 | PHASE2 | BHV-8000 |
| AC Immune SA | ACIU | 2 | PHASE2 | ACI-7104.056 |
| Eli Lilly and Company | LLY | 4 | PHASE1 | LY3884961, LY4006896, LY3962681 |
| Gain Therapeutics, Inc. | GANX | 2 | PHASE2 | GT-02287 |
| Annovis Bio Inc | ANVS | 1 | PHASE2 | Buntanetap |
| Regeneron Pharmaceuticals, Inc. | REGN | 2 | PHASE1 | ALN-SNCA |
| MeiraGTx Holdings Plc | MGTX | 1 | PHASE1 | AAV-GAD |
| Serina Therapeutics, Inc. | SER | 1 | PHASE1 | SER-252 |
| Ardelyx, Inc. | ARDX | 1 | PHASE2 | Tenapanor |
| Hoffmann-La Roche | RHHBY | 1 | PHASE1 | RO7568282 |
| Merck & Co., Inc. | MRK | 1 | EARLY_PHASE1 | MK-0947 |
MK-0947 is an imaging agent being studied for use in Parkinson's disease. It is designed to evaluate alpha-synuclein deposition in the brain using positron emission tomography (PET). It is not a treatment for Parkinson's disease; it is a diagnostic tool intended to help visualize a key protein associated with the condition.
MK-0947 is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. Merck is the sponsor of the clinical research program for this imaging agent.
MK-0947 is in Phase 1 clinical development. The only registered trial is an early Phase 1 study, and it is currently recruiting participants. The drug is investigational and has not been approved by the FDA.
MK-0947 is being studied in one clinical trial, NCT07348250, titled "Open-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's Disease." The trial is recruiting and plans to enroll 22 participants in the United States.
Yes, MK-0947 is also known as [18F]MK-0947. The bracketed notation indicates the molecule is labeled with fluorine-18, a radioactive isotope used in PET imaging. Both names refer to the same investigational imaging agent.